Close Menu

NEW YORK (GenomeWeb) – CareDx announced today that it plans to sell 2 million shares of its common stock in a public offering and expects to raise about $49 million in proceeds.

The firm has priced the offering at $24.50 per share and has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares. Net proceeds from the offering are expected to be approximately $45.9 million after deducting underwriting discounts and commissions. The offering is expected to close on or about Nov. 16.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News examines how science in the UK may fare as Boris Johnson, the next prime minister, pursues Brexit.

CNN reports that Immigration and Customs Enforcement in the US has expanded its DNA testing to seven sites along the southern border.

In PNAS this week: role for exosomes in neuronal circuit development, tuberculosis pathogen enzymes, and more.

Undoing Obamacare protections could affect people's willingness to undergo genetic testing, Sarah Lawrence College's Laura Hercher and the University of Iowa College of Law's Anya Prince write at BuzzFeed News.